Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era

Published:2022-08-25 Issue:8 Volume:5 Page:e2225459
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Lamba Nayan¹,Ott Patrick A.²,Iorgulescu J. Bryan³

Affiliation:

1. Harvard Radiation Oncology Program, Boston, Massachusetts

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

3. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2795637/lamba_2022_oi_220711_1660829915.27318.pdf

Reference40 articles.

1. Melanoma.;Schadendorf;Lancet,2018

2. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.;Dobry;Cancer Immunol Immunother,2018

3. NCCN Guidelines insights: melanoma, version 3.2016: featured updates to the NCCN Guidelines.;Coit;J Natl Compr Canc Netw,2016

4. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.;Hamid;Eur J Cancer,2017

5. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.;Ribas;Lancet Oncol,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment;Respirology Case Reports;2024-09

2. Targeting anticancer immunity in melanoma tumour microenvironment: unleashing the potential of adjuvants, drugs, and phytochemicals;Journal of Drug Targeting;2024-08-07

3. Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients;Scientific Reports;2024-07-18

4. Learning About and Living With Toxicity: A Qualitative Study of Patients Receiving Immune Checkpoint Inhibitors For Melanoma or Lung Cancer and Their Caregivers;2024-07-04

5. Efficacy and safety of PD-1 Monoclonal antibodies in the treatment of esophageal squamous cell carcinoma: Systematic review and meta Regression;Heliyon;2024-07